Mark Thalgott1, Martina Kron2, Johannes M Brath3, Donna P Ankerst4, Ian M Thompson5, Juergen E Gschwend3, Kathleen Herkommer3. 1. Department of Urology, Urologische Klinik und Poliklinik, der Technische Universität München, Klinikum rechts der Isar, Ismaninger Str. 22, 81675, Munich, Germany. mark.thalgott@tum.de. 2. Institute of Biometrics, University of Ulm, Ulm, Germany. 3. Department of Urology, Urologische Klinik und Poliklinik, der Technische Universität München, Klinikum rechts der Isar, Ismaninger Str. 22, 81675, Munich, Germany. 4. Departments of Life Sciences and Mathematics of the Technical University Munich, Munich, Germany. 5. Department of Urology, University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, San Antonio, USA.
Abstract
PURPOSE: We aimed to determine if family history (FH) of prostate cancer (PC) influenced cancer control after radical prostatectomy (RP). METHODS: Patients were evaluated in a prospectively-collected PC family database: The focus was on hereditary prostate cancer (HPC) defined by Johns Hopkins criteria and sporadic prostate cancer (SPC), rigorously defined by absence of prostate cancer in ≥ 2 brothers aged ≥ 60 years. Additionally, patients with first-degree (FPC) and non-first-degree PC (non-FPC) were assessed. Endpoints were biochemical recurrence-free survival (BRFS) and prostate cancer-specific survival (CSS). Finally, clinico-pathological characteristics were compared and multiple proportional hazards regression was used to identify prognostic factors. RESULTS: In total 11,654 patients were included (807 HPC, 2251 FPC, 8072 non-FPC and 524 SPC). Familial imposition (HPC/FPC) was associated with a younger age at diagnosis. Thus, HPC patients were diagnosed 2.9 years earlier than SPC patients with more locally advanced tumors (≥ pT3). With a median follow up of 6.2 years (range 0-31.5) BRFS was significantly different when stratified by FH. In pairwise analyses BRFS differed significantly for HPC compared to SPC (HR = 1.27). Consecutively FH was identified as prognostic factor for BRFS (p = 0.021) together with age, PSA, pathologic characteristics and adjuvant androgen deprivation. Analyses of CSS did not show a difference. CONCLUSION: Patients with FH of PC are likely to be diagnosed earlier and present a higher proportion of locally advanced disease. In addition, men with FH are at higher risk of biochemical recurrence after surgery but reveal similar outcomes regarding prostate cancer-specific survival.
PURPOSE: We aimed to determine if family history (FH) of prostate cancer (PC) influenced cancer control after radical prostatectomy (RP). METHODS:Patients were evaluated in a prospectively-collected PC family database: The focus was on hereditary prostate cancer (HPC) defined by Johns Hopkins criteria and sporadic prostate cancer (SPC), rigorously defined by absence of prostate cancer in ≥ 2 brothers aged ≥ 60 years. Additionally, patients with first-degree (FPC) and non-first-degree PC (non-FPC) were assessed. Endpoints were biochemical recurrence-free survival (BRFS) and prostate cancer-specific survival (CSS). Finally, clinico-pathological characteristics were compared and multiple proportional hazards regression was used to identify prognostic factors. RESULTS: In total 11,654 patients were included (807 HPC, 2251 FPC, 8072 non-FPC and 524 SPC). Familial imposition (HPC/FPC) was associated with a younger age at diagnosis. Thus, HPCpatients were diagnosed 2.9 years earlier than SPC patients with more locally advanced tumors (≥ pT3). With a median follow up of 6.2 years (range 0-31.5) BRFS was significantly different when stratified by FH. In pairwise analyses BRFS differed significantly for HPC compared to SPC (HR = 1.27). Consecutively FH was identified as prognostic factor for BRFS (p = 0.021) together with age, PSA, pathologic characteristics and adjuvant androgen deprivation. Analyses of CSS did not show a difference. CONCLUSION:Patients with FH of PC are likely to be diagnosed earlier and present a higher proportion of locally advanced disease. In addition, men with FH are at higher risk of biochemical recurrence after surgery but reveal similar outcomes regarding prostate cancer-specific survival.
Entities:
Keywords:
Family history; Hereditary prostate cancer; Radical prostatectomy; Sporadic prostate cancer
Authors: Sameer A Siddiqui; Shomik Sengupta; Jeffrey M Slezak; Eric J Bergstralh; Horst Zincke; Michael L Blute Journal: J Urol Date: 2006-09 Impact factor: 7.450
Authors: Lasse Saarimäki; Teuvo L Tammela; Liisa Määttänen; Kimmo Taari; Paula M Kujala; Jani Raitanen; Anssi Auvinen Journal: Int J Cancer Date: 2014-10-10 Impact factor: 7.396
Authors: Danielle M Karyadi; Shanshan Zhao; Qianchuan He; Laura McIntosh; Jonathan L Wright; Elaine A Ostrander; Ziding Feng; Janet L Stanford Journal: Int J Cancer Date: 2014-10-13 Impact factor: 7.396
Authors: Patrick A Kupelian; Chandana A Reddy; Alwyn M Reuther; Arul Mahadevan; Jay P Ciezki; Eric A Klein Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544
Authors: Kristen S Purrington; Ann G Schwartz; Julie J Ruterbusch; Mark A Manning; Mrudula Nair; Angela S Wenzlaff; Stephanie S Pandolfi; Michael S Simon; Jennifer Beebe-Dimmer Journal: Cancer Date: 2020-08-04 Impact factor: 6.860
Authors: Valentin H Meissner; Jamila G H Strüh; Martina Kron; Lea A Liesenfeld; Stephanie Kranz; Jürgen E Gschwend; Kathleen Herkommer Journal: World J Urol Date: 2020-03-11 Impact factor: 4.226
Authors: Olga Golubnitschaja; Peter Kubatka; Alena Mazurakova; Marek Samec; Abdullah Alajati; Frank A Giordano; Vincenzo Costigliola; Jörg Ellinger; Manuel Ritter Journal: Cancers (Basel) Date: 2022-01-28 Impact factor: 6.639